Decreased Tenofovir Diphosphate Concentrations in a Transgender Female Cohort: Implications for Human Immunodeficiency Virus Preexposure Prophylaxis

被引：40
|
作者：
Cottrell, Mackenzie L. [1 ]
Prince, Heather M. A. [2 ]
Schauer, Amanda P. [1 ]
Sykes, Craig [1 ]
Maffuid, Kaitlyn [1 ]
Poliseno, Amanda [1 ]
Chun, Tae-Wook [3 ]
Huiting, Erin [3 ]
Stanczyk, Frank Z. [4 ]
Peery, Anne F. [5 ]
Dellon, Evan S. [5 ]
Adams, Jessica L. [6 ,7 ]
Gay, Cindy [2 ]
Kashuba, Angela D. M. [1 ,2 ]
机构：
[1] Univ N Carolina, Eshelman Sch Pharm, Div Pharmacotherapy & Expt Therapeut, Chapel Hill, NC 27515 USA
[2] Univ N Carolina, Div Infect Dis, Sch Med, Chapel Hill, NC 27515 USA
[3] NIAID, HIV Immunovirol Unit, 9000 Rockville Pike, Bethesda, MD 20892 USA
[4] Univ Southern Calif, Keck Sch Med, Los Angeles, CA 90007 USA
[5] Univ N Carolina, Sch Med, Div Gastroenterol & Hepatol, Chapel Hill, NC 27515 USA
[6] Univ Sci, Philadelphia Coll Pharm, Philadelphia, PA USA
[7] Cooper Univ Hosp, Early Intervent Program, Camden, NJ USA
来源：
CLINICAL INFECTIOUS DISEASES | 2019年 / 69卷 / 12期
基金：
美国国家卫生研究院;
关键词：
transgender; preexposure prophylaxis; lower gastrointestinal tract; HIV; feminizing hormone therapy; HIV; WOMEN; NUCLEOTIDE;
D O I：
10.1093/cid/ciz290
中图分类号：
R392 [医学免疫学]; Q939.91 [免疫学];
学科分类号：
100102 ;
摘要：
Feminizing hormone therapy (FHT) may interact with human immunodeficiency virus preexposure prophylaxis (PrEP). We found that transgender women who took FHT exhibited a 7-fold lower rectal tissue ratio of PrEP's active metabolites vs competing deoxynucleotides compared to cisgender women and men (P = .03) that inversely correlated with estradiol (rho = -0.79; P < .05). Thus, FHT may negatively impact PrEP efficacy.
引用
收藏
页码：2201 / 2204
页数：4
相关论文
共 50 条
  • [1] Human Immunodeficiency Virus Preexposure Prophylaxis: Meeting the Needs of Transgender Populations
    Krakower, Douglas S.
    CLINICAL INFECTIOUS DISEASES, 2021, 73 (07) : E2124 - E2126
  • [2] Systemic Preexposure Prophylaxis for Human Immunodeficiency Virus Infection
    Romanelli, Frank
    Murphy, Brian
    PHARMACOTHERAPY, 2010, 30 (10): : 1021 - 1030
  • [3] Depot Medroxyprogesterone Acetate and the Vaginal Microbiome as Modifiers of Tenofovir Diphosphate and Lamivudine Triphosphate Concentrations in the Female Genital Tract of Ugandan Women: Implications for Tenofovir Disoproxil Fumarate/Lamivudine in Preexposure Prophylaxis
    Nicol, Melanie R.
    Eneh, Prosperity
    Nakalega, Rita
    Kaiser, Thomas
    Kabwigu, Samuel
    Isingel, Esther
    Beksinska, Mags
    Sykes, Craig
    Fowler, Mary Glenn
    Brown, Todd T.
    Staley, Christopher
    Matovu, Flavia Kiweewa
    CLINICAL INFECTIOUS DISEASES, 2020, 70 (08) : 1717 - 1724
  • [4] Concentrations of Tenofovir and Emtricitabine in Saliva: Implications for Preexposure Prophylaxis of Oral HIV Acquisition
    de Lastours, Victoire
    Fonsart, Julien
    Burlacu, Ruxandra
    Gourmel, Bernard
    Molina, Jean-Michel
    ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 2011, 55 (10) : 4905 - 4907
  • [5] Switching From Tenofovir Disoproxil Fumarate to Tenofovir Alafenamide for Human Immunodeficiency Virus Preexposure Prophylaxis at a Boston Community Health Center
    Marcus, Julia L.
    Levine, Kenneth
    Sewell, Whitney C.
    Solleveld, Patricia
    Mayer, Kenneth H.
    Krakower, Douglas S.
    OPEN FORUM INFECTIOUS DISEASES, 2021, 8 (08):
  • [6] Factors Influencing Willingness to Use Human Immunodeficiency Virus Preexposure Prophylaxis Among Transgender Women in India
    Chakrapani, Venkatesan
    Shaikh, Simran
    Arumugam, Visvanathan
    Chawla, Umesh
    Mehta, Sonal
    TRANSGENDER HEALTH, 2021, 6 (02) : 64 - 73
  • [7] Preexposure Prophylaxis Acceptability Among Pregnant Individuals and Implications for Human Immunodeficiency Virus Prevention
    Groves, Allison K.
    Vadaketh, Jessica
    Raziano, Valerie T.
    Nkwihoreze, Hervette
    Short, William R.
    Momplaisir, Florence
    OBSTETRICS AND GYNECOLOGY, 2022, 139 (04): : 537 - 544
  • [8] Tenofovir and tenofovir-diphosphate concentrations during pregnancy among HIV-uninfected women using oral preexposure prophylaxis
    Pyra, Maria
    Anderson, Peter L.
    Hendrix, Craig W.
    Heffron, Renee
    Mugwanya, Kenneth
    Haberer, Jessica E.
    Thomas, Katherine K.
    Celum, Connie
    Donnell, Deborah
    Marzinke, Mark A.
    Bukusi, Elizabeth A.
    Mugo, Nelly R.
    Asiimwe, Stephen
    Katabira, Elly
    Baeten, Jared M.
    AIDS, 2018, 32 (13) : 1891 - 1898
  • [9] Human Immunodeficiency Virus Preexposure Prophylaxis in Adolescents and Young Adults
    Brundrett, Megan E.
    PEDIATRICS IN REVIEW, 2021, 43 (01) : 28 - 36
  • [10] Human Immunodeficiency Virus Preexposure Prophylaxis in Adolescents and Young Adults
    Brundrett, Megan E.
    PEDIATRICS IN REVIEW, 2022, 43 (01) : 28 - 36
12345